Caprion Identifies Protein Biomarkers for Predicting Patient Response to New Hepatitis C Drug
October 22, 2010
Caprion Identifies Protein Biomarkers for Predicting Patient Response to New Hepatitis C Drug
The company said that the biomarkers were correlated with sustained viral response or viral cure in response to a combined treatment of pegylated-interferon, ribavirin, and telaprevir, a drug candidate for hepatitis C.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Research into Cancer, Diabetes, and Other Diseases Puts Spotlight on Clinical Proteomics at HUPO
October 1, 2009 / ProteoMonitor - Agilent and Integrated Diagnostics Partner on Protein Biomarker Assays
January 10, 2012 / GenomeWeb Daily News - FHS Researchers Develop Multi-Biomarker Panel to Predict Risk of Chronic Kidney Disease
October 22, 2010 / ProteoMonitor - PSTC Paper Provides Inside Look at FDA and EMEA Biomarker Approval Process
May 14, 2010 / ProteoMonitor - Protea Licenses Cardiovascular Biomarker Tech from Hopkins
July 21, 2009 / GenomeWeb Daily News